WO2013004076A8 - Agr2阻断抗体及其用途 - Google Patents

Agr2阻断抗体及其用途 Download PDF

Info

Publication number
WO2013004076A8
WO2013004076A8 PCT/CN2012/000926 CN2012000926W WO2013004076A8 WO 2013004076 A8 WO2013004076 A8 WO 2013004076A8 CN 2012000926 W CN2012000926 W CN 2012000926W WO 2013004076 A8 WO2013004076 A8 WO 2013004076A8
Authority
WO
WIPO (PCT)
Prior art keywords
agr2
blocking antibody
antibody
blocking
disclosed
Prior art date
Application number
PCT/CN2012/000926
Other languages
English (en)
French (fr)
Other versions
WO2013004076A1 (zh
Inventor
李大伟
武正华
郭昊
朱奇
马绍司
Original Assignee
赛诺菲(中国)投资有限公司上海分公司
上海交通大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020147003059A priority Critical patent/KR20140093922A/ko
Application filed by 赛诺菲(中国)投资有限公司上海分公司, 上海交通大学 filed Critical 赛诺菲(中国)投资有限公司上海分公司
Priority to US14/130,767 priority patent/US9574012B2/en
Priority to MX2014000260A priority patent/MX347320B/es
Priority to AU2012278751A priority patent/AU2012278751B2/en
Priority to BR112014000181A priority patent/BR112014000181A2/pt
Priority to RU2014103784A priority patent/RU2610665C2/ru
Priority to CA2841372A priority patent/CA2841372A1/en
Priority to JP2014517400A priority patent/JP6127043B2/ja
Priority to CN201280033663.2A priority patent/CN103987731B/zh
Priority to EP12807760.9A priority patent/EP2749573B1/en
Publication of WO2013004076A1 publication Critical patent/WO2013004076A1/zh
Publication of WO2013004076A8 publication Critical patent/WO2013004076A8/zh
Priority to US15/402,996 priority patent/US20170240651A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明公开了一种AGR2阻断性单克隆抗体，尤其是一种阻断AGR2的人源化单克隆抗体。本发明还公开了包含所述抗体的药物组合物及其制备方法，以及所述抗体用于阻断肿瘤生长和转移的用途。
PCT/CN2012/000926 2011-07-05 2012-07-05 Agr2阻断抗体及其用途 WO2013004076A1 (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
RU2014103784A RU2610665C2 (ru) 2011-07-05 2012-07-05 Антитело, блокирующее agr2, и его применение
US14/130,767 US9574012B2 (en) 2011-07-05 2012-07-05 AGR2 blocking antibody and use thereof
MX2014000260A MX347320B (es) 2011-07-05 2012-07-05 Anticuerpo bloqueador de agr2 y uso del mismo.
AU2012278751A AU2012278751B2 (en) 2011-07-05 2012-07-05 AGR2 blocking antibody and use thereof
BR112014000181A BR112014000181A2 (pt) 2011-07-05 2012-07-05 bloqueamento de anticorpo agr2 e uso dos mesmos
KR1020147003059A KR20140093922A (ko) 2011-07-05 2012-07-05 Ａｇｒ２ 차단 항체 및 그의 용도
CA2841372A CA2841372A1 (en) 2011-07-05 2012-07-05 Agr2 blocking antibody and use thereof
EP12807760.9A EP2749573B1 (en) 2011-07-05 2012-07-05 Agr2 blocking antibody and use thereof
CN201280033663.2A CN103987731B (zh) 2011-07-05 2012-07-05 Agr2阻断抗体及其用途
JP2014517400A JP6127043B2 (ja) 2011-07-05 2012-07-05 Ａｇｒ２遮断抗体及びその使用
US15/402,996 US20170240651A1 (en) 2011-07-05 2017-01-10 Agr2 blocking antibody and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110186469.5 2011-07-05
CN2011101864695A CN102268089A (zh) 2011-07-05 2011-07-05 Agr2阻断抗体及其用途

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/130,767 A-371-Of-International US9574012B2 (en) 2011-07-05 2012-07-05 AGR2 blocking antibody and use thereof
US15/402,996 Continuation US20170240651A1 (en) 2011-07-05 2017-01-10 Agr2 blocking antibody and use thereof

Publications (2)

Publication Number Publication Date
WO2013004076A1 WO2013004076A1 (zh) 2013-01-10
WO2013004076A8 true WO2013004076A8 (zh) 2014-02-06

Family

ID=45050566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/000926 WO2013004076A1 (zh) 2011-07-05 2012-07-05 Agr2阻断抗体及其用途

Country Status (13)

Country Link
US (2) US9574012B2 (zh)
EP (1) EP2749573B1 (zh)
JP (1) JP6127043B2 (zh)
KR (1) KR20140093922A (zh)
CN (2) CN102268089A (zh)
AU (1) AU2012278751B2 (zh)
BR (1) BR112014000181A2 (zh)
CA (1) CA2841372A1 (zh)
MX (1) MX347320B (zh)
RU (1) RU2610665C2 (zh)
SG (1) SG10201605435TA (zh)
TW (1) TWI588154B (zh)
WO (1) WO2013004076A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102268089A (zh) * 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
KR101588285B1 (ko) * 2013-06-04 2016-01-25 한국생명공학연구원 소포체 스트레스로 인한 세포사멸을 약화시키는 agr2 호모-다이머
US8999007B2 (en) * 2013-07-12 2015-04-07 Ostara Nutrient Recovery Technologies Inc. Method for fines control
US9790488B2 (en) 2013-08-02 2017-10-17 Agency For Science, Technology And Research Mutated internal ribosomal entry site (IRES) for controlled gene expression
KR20170058960A (ko) * 2014-09-09 2017-05-29 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 Agr2 및 그의 수용체 c4.4a 에 대한 차단 모노클로날 항체
CN104593333B (zh) * 2014-12-12 2017-07-21 上海交通大学 稳定表达抗agr2人源化单克隆抗体的cho细胞株及其应用
KR101634612B1 (ko) * 2015-12-29 2016-06-29 한국생명공학연구원 소포체 스트레스로 인한 세포사멸을 약화시키는 agr2 호모-다이머
WO2017156280A1 (en) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
CA3109716A1 (en) * 2018-08-30 2020-03-05 Universite De Montreal Proteogenomic-based method for identifying tumor-specific antigens
US20210340278A1 (en) 2018-10-04 2021-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
CN109576229A (zh) * 2018-12-13 2019-04-05 华中科技大学同济医学院附属协和医院 一种分泌抗agr2的单克隆抗体杂交瘤细胞株及其应用
CN113336853B (zh) * 2020-11-04 2022-06-14 华中科技大学同济医学院附属协和医院 针对agr3蛋白的单克隆抗体、制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1928506A4 (en) 2005-08-19 2009-10-21 Abbott Lab IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
GB0616929D0 (en) * 2006-08-26 2006-10-04 Univ Liverpool Antibodies, assays and hybridomas
EP2310526A4 (en) * 2008-07-18 2011-11-02 Oragenics Inc COMPOSITIONS FOR THE DETECTION AND TREATMENT OF COLORECTAL CANCER
KR100983386B1 (ko) * 2008-09-12 2010-09-20 성균관대학교산학협력단 난소암 진단을 위한 ａｇｒ-2의 신규한 용도
CN101519649B (zh) * 2009-01-22 2010-11-03 上海交通大学 杂交瘤细胞株及其制备方法
WO2012100339A1 (en) * 2011-01-27 2012-08-02 University Health Network Methods and compositions for the detection of pancreatic cancer
WO2012116357A2 (en) * 2011-02-25 2012-08-30 The Board Of Trustees Of The Leland Use of agr3 for treating cancer
CN102268089A (zh) * 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
JP6127043B2 (ja) 2017-05-10
MX347320B (es) 2017-04-21
BR112014000181A2 (pt) 2017-02-07
AU2012278751A1 (en) 2014-02-27
RU2014103784A (ru) 2015-08-10
US20140328829A1 (en) 2014-11-06
KR20140093922A (ko) 2014-07-29
RU2610665C2 (ru) 2017-02-14
EP2749573A4 (en) 2015-03-04
CA2841372A1 (en) 2013-01-10
US20170240651A1 (en) 2017-08-24
TW201319085A (zh) 2013-05-16
EP2749573B1 (en) 2017-09-13
CN102268089A (zh) 2011-12-07
JP2014520511A (ja) 2014-08-25
AU2012278751B2 (en) 2017-07-20
AU2012278751A8 (en) 2014-03-27
CN103987731B (zh) 2018-04-13
WO2013004076A1 (zh) 2013-01-10
US9574012B2 (en) 2017-02-21
CN103987731A (zh) 2014-08-13
MX2014000260A (es) 2014-09-01
TWI588154B (zh) 2017-06-21
SG10201605435TA (en) 2016-08-30
EP2749573A1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
WO2013004076A8 (zh) Agr2阻断抗体及其用途
HK1256304A1 (zh) 用於生成單克隆抗體的方法和試劑
EP2540745A4 (en) COMPLETELY HUMANIZED ANTI-HER2 ANTIBODY, MANUFACTURING METHOD AND USE
IL245274B (en) Monoclonal antibodies against the 2her epitope
EP3470427A4 (en) MONOCLONAL INTERLEUKIN-17A HUMAN ANTIBODIES, PREPARATION METHOD AND USE THEREOF
IL222359A0 (en) Monoclonal antibodies against her2 antigens, and uses therefor
IL228802A0 (en) Bispecific antibodies against 2her and 3cd
DK3323834T3 (en) Anti-cd40 antibodies, uses and methods
EP2748199A4 (en) ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
MX347020B (es) Anticuerpo contra el csf-1r.
EP2775305A4 (en) FLUORO-IMMUNOLOGY ASSAY METHOD USING A POLYPEPTIDE COMPLEX CONTAINING A VARIABLE FLUOROMARCATED ANTIBODY REGION
MX2013011012A (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
EP2540743A4 (en) COMPLETELY HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, PREPARATION METHOD AND USE THEREOF
EP2771694A4 (en) MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
EP3091030A4 (en) Anti-human rankl antibody, humanized antibody, pharmaceutical compositions and uses thereof
NZ597531A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists
EP2742067A4 (en) MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
EP2575882A4 (en) HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
EP3242895A4 (en) A novel anti-egfr monoclonal antibody, method of making, and use thereof
EP3722311A4 (en) HUMAN ANTI-IL6 MONOCLONAL ANTIBODIES, METHOD FOR THE PREPARATION AND USE THEREOF
EP2475383A4 (en) FOR THE PEPTIDE PRODUCED FROM HSP65 6 SPECIFIC HUMANIZED ANTIBODIES AND USES THEREOF
WO2013138244A3 (en) Treatment of multiple sclerosis with anti-cd19 antibody
EP2700650A4 (en) MONOCLONAL ANTIBODIES FOR THE SPECIFIC DETECTION OF HUMAN LIVER CARBOXYL ETERASE 1, HYBRIDOMA CELL LINES FOR THE MANUFACTURE OF MONOCLONAL ANTIBODIES AND USES THEREOF
WO2013186630A3 (en) Humanized antibodies to ca215

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12807760

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase in:

Ref document number: 2014517400

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2841372

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/000260

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2012807760

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012807760

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 20147003059

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2014103784

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2012278751

Country of ref document: AU

Date of ref document: 20120705

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014000181

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 14130767

Country of ref document: US

ENP Entry into the national phase in:

Ref document number: 112014000181

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140106